Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

Stock Information for Theralase Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Theralase Technologies Inc.

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase(R) Investor Conference Call Reminder
Theralase(R) Releases 3Q2025 Financial Statements
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Theralase(R) Extends Warrants
Theralase(R) Releases 2Q2025 Financial Statements

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.